Orthovisc

Orthovisc

Orthopedics An injectable hyaluronic acid for treating osteoarthritis of the knee; viscoelastic and lubricating properties are similar to normal synovial fluid. See Hyaluronic acid.
References in periodicals archive ?
market to combine triamcinolone hexacetonide, a well-established, FDA-approved steroid utilized to treat inflammation, with Anika's proprietary cross-linked, non-animal-derived hyaluronic acid, which is the active ingredient in the company's global market-leading viscosupplements, ORTHOVISC and MONOVISC.
Cingal is the first and only viscosupplement that combines triamcinolone hexacetonide, a well-established, FDA-approved steroid that may be utilized to treat inflammation, with Anika's proprietary cross-linked, non-animal-derived hyaluronic acid, which is the active "cushioning" ingredient in the global market-leading viscosupplements, Orthovisc and Monovisc.
The current commercialisation agreement allows Anika to supply CINGAL to Pendopharm for sale in the Canadian market, where Pendopharm is Anika's sole commercialisation partner for its ORTHOVISC and MONOVISC products.
has introduced Orthovisc (high-molecular-weight hyaluronan), a new treatment option for patients suffering from pain due to osteoarthritis.
Under the agreement, Anika will receive an initial payment of $2 million and payments upon receipt of final marketing approval for ORTHOVISC from the U.
Orthovisc is a natural product made from sodium hyaluronate, which comes from the combs of roosters.
In conjunction, the company maintains a market leadership position in the US and a growing presence internationally, with its multi-injection product, ORTHOVISC and its single-injection product, MONOVISC.
Due to the catastrophic earthquake in Turkey on August 17, we have honored the request of our Turkish distributor, Biomeks Pharmaceuticals, to delay the delivery of certain ORTHOVISC orders until the fourth quarter of 1999.
Cingal is Anika's third-generation viscosupplement, following the company's Orthovisc and Monovisc products, to treat pain associated with osteoarthritis of the knee.
According to the company, the revenue growth was primarily driven by strong domestic and international sales of its flagship product, Orthovisc, growing international sales of Monovisc and shipments of orthopedic and surgical products.
Product revenue was higher in every product category, with the majority of the product revenue increase represented by the combined sales of Monovisc and Orthovisc, Helix said.
Anika and DePuy Mitek have yielded mutual benefits form their earlier partnership on Anika's initial viscosupplementation product, ORTHOVISC, and has now expanded their productive collaboration to the MONOVISC product.